{"id":10422,"date":"2017-07-10T00:00:00","date_gmt":"2017-07-09T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2017\/07\/10\/nova-eina-danalisi-per-a-predir-la-resposta-al-tractament-preoperatori-en-cancer-de-recte\/"},"modified":"2020-05-19T18:48:42","modified_gmt":"2020-05-19T16:48:42","slug":"nova-eina-danalisi-per-a-predir-la-resposta-al-tractament-preoperatori-en-cancer-de-recte","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2017\/07\/nova-eina-danalisi-per-a-predir-la-resposta-al-tractament-preoperatori-en-cancer-de-recte\/","title":{"rendered":"Nova eina d\u2019an\u00e0lisi per a predir la resposta al tractament preoperatori en c\u00e0ncer de recte"},"content":{"rendered":"<p>Investigadors del Programa Contra la Resist\u00e8ncia Terap\u00e8utica del C\u00e0ncer (ProCURE), de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) han desenvolupat una nova eina que permet establir la probabilitat de resposta al tractament preoperatori en tumors de recte localment avan\u00e7ats. Predir quins pacients no respondran al tractament pot ajudar a evitar efectes secundaris innecessaris i permetr\u00e0 oferir-los alternatives m\u00e9s beneficioses, com poden ser la cirurgia programada amb major antel\u00b7laci\u00f3 o la participaci\u00f3 en estudis cl\u00ednics. Aquest treball ha estat publicat a la prestigiosa revista cient\u00edfica <em>\u2018Annals of Oncology\u2019<\/em>. <b><br \/> <em>\u201cDins l\u2019espectre del c\u00e0ncer colorectal, el c\u00e0ncer de recte localment avan\u00e7at (LARC) \u00e9s l\u2019\u00fanic cas cl\u00ednic en qu\u00e8 es prescriu sistem\u00e0ticament un tractament quimioter\u00e0pic previ a la cirurgia<\/em>\u201d, explica el l\u00edder de l\u2019estudi i cap del grup de recerca en resist\u00e8ncia i microentorn tumoral, David Garc\u00eda-Monllevi. <em>\u201cNo obstant, a dia d\u2019avui, \u00e9s molt dif\u00edcil predir la resposta dels pacients a aquest tractament preoperatori; se sap que al voltant d\u2019un 60% dels pacients de LARC no hi respondran, per\u00f2 fins ara no es disposava de marcadors prou robustos per identificar-los\u201d<\/em> afegeix Garc\u00eda-Mollev\u00ed. <b><br \/> <b><br \/> Amb l\u2019ajuda d\u2019un microscopi de captura l\u00e0ser i eines d\u2019an\u00e0lisi de RNA, l\u2019investigador Samuel Gon\u00e7alves va caracteritzar diverses zones d\u2019una s\u00e8rie de tumors, distingint entre les c\u00e8l\u00b7lules tumorals i les de l\u2019estroma, el teixit que l\u2019envolta. Comparant els resultats de l\u2019an\u00e0lisi entre pacients que hi havia repost i pacients que no, els investigadors de l\u2019IDIBELL-ICO van observar que les pr\u00f2pies c\u00e8l\u00b7lules tumorals no presentaven diferencies significatives. En canvi, l\u2019estroma tumoral era molt diferent entre ambd\u00f3s tipus de pacients, fet que podia convertir-lo en una gran font de biomarcadors predictors. Concretament, i despr\u00e9s d\u2019un proc\u00e9s de refinament, van identificar 5 gens clau susceptibles d\u2019esdevenir biomarcadors de la resposta al tractament. <b><br \/> <em>\u201cUn cop ten\u00edem identificats els gens, vam traslladar els resultats a nivell proteic per tal de dissenyar una eina immunohistoqu\u00edmica econ\u00f2mica, reprodu\u00efble i amb m\u00e9s rellev\u00e0ncia biol\u00f2gica; tamb\u00e9 vam aconseguir reduir l\u2019an\u00e0lisi a tan sols dues prote\u00efnes del estroma, la fibronectina i el col\u00b7lagen 3\u201d,<\/em> destaca Garc\u00eda-Mollev\u00ed. Aquesta nova eina de predicci\u00f3 immunohistoqu\u00edmica ha estat validada en una cohort amb dades provinents de 36 pacients, assolint una probabilitat d\u2019encert del 88% quan el test \u00e9s positiu, \u00e9s a dir, quan prediu que el pacient no respondr\u00e0 al tractament. Un cop publicats aquests resultats, els investigadors de l\u2019IDIBELL-ICO es plantegen ampliar la validaci\u00f3 de l\u2019eina en un estudi prospectiu multic\u00e8ntric amb un nombre m\u00e9s gran de participants<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Investigadors del Programa Contra la Resist\u00e8ncia Terap\u00e8utica del C\u00e0ncer (ProCURE), de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) han desenvolupat una nova eina que permet establir la probabilitat de resposta al tractament preoperatori en tumors de recte localment avan\u00e7ats. Predir quins pacients no respondran al tractament pot ajudar a evitar [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":10423,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[184,281,206],"tags":[],"class_list":["post-10422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-area-cancer","category-programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell","category-quimioresistencia-tumoral-y-estromal"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 01:44:29","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/10422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=10422"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/10422\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/10423"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=10422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=10422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=10422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}